Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
Data Insights
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...